Bromide

Bromide

SCHEMBL582107

Br.Fc1cc(C[Zn])ccc1C(F)(F)F

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 13/20 0.53
DAO P14920 1/20 0.46
KDM1A O60341 1/20 0.41
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
P2RX7 Q99572 1/20 0.37
TAAR1 Q96RJ0 1/20 0.36
FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL28322451 0.82 KIF11 (0.51) KIF11DAOKDM1ACYP11B1CYP11B2
SCHEMBL29889972 0.79 KIF11 (0.53) KIF11DAOKDM1ACYP11B1CYP11B2
SCHEMBL5138665 0.79 KIF11 (0.53) KIF11DAOKDM1ACYP11B1CYP11B2
SCHEMBL30139652 0.79 KIF11 (0.53) KIF11DAOKDM1ATAAR1
SCHEMBL12706035 0.79 KIF11 (0.53) KIF11DAOKDM1ACYP11B1CYP11B2
SCHEMBL297408 0.79 KIF11 (0.53) KIF11DAOKDM1ATAAR1
SCHEMBL698164 0.79 KIF11 (0.53) KIF11DAOKDM1ACYP11B1CYP11B2
SCHEMBL696163 0.79 KIF11 (0.53) KIF11DAOKDM1ACYP11B1CYP11B2
SCHEMBL92971 0.79 KIF11 (0.73) KIF11DAOKDM1ACYP11B1CYP11B2
SCHEMBL19356858 0.79 KIF11 (0.53) KIF11DAOKDM1ACYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 US disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 EP disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 KIF11 3415/4885DAO 583/4885KDM1A 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.